Konica Minolta, Inc.

Konica Corporation

Konica Minolta Medical and Graphic, Inc.

Konica-minolta Holdings, Inc.

Hisatake Okada

Yasushi Nakano

Noriaki Ohuchi

Kohsuke Gonda

Hideki Hoshino

Naoko Furusawa

Mika Watanabe

Kensaku Takanashi

Hideki Gouda

Satoshi Ito

Kazuya Tsukada

Motohiro Takeda

Akinori Tsunomori

Takuji Aimiya

Hideki Goda

Hiroshi Kita

Masaru Takahashi

Tetsuya Yamamoto

Kazuyoshi Goan

Yuichi Ozaki

Shigetami Kasai

Mitsuru Sekiguchi

Masayuki Ushiku

Daisuke Ishibashi

Yuka Yoshihara

Norikazu Masuda

Masakazu Toi

Hiroshi Tada

Noriko Ohara

Minoru Miyashita

It is an object of the present invention to provide a tissue staining method that makes it possible to observe both information on the morphology of a tissue and information on a biological substance such as an antigen molecule to be detected on a single section and in a single view field. The present invention provides a tissue staining method, including carrying out (A) a HE (hematoxylin-eosin) staining, and (B) a histochemical staining, serially on a single tissue section, wherein the histochemical staining is defined as a histochemical technique for detecting a biological substance to be detected in a tissue in a visible manner by use of a binding reaction between the biological substance to be detected and a probe biological substance capable of binding specifically to the biological substance to be detected.

Tissue staining method

A biological substance detection method for detecting a biological substance specifically in a pathological specimen, includes a step of immunologically staining the pathological specimen using a fluorescent label, a step of staining the pathological specimen with a staining reagent for morphology observation purposes (eosin) to observe the morphology of the pathological specimen, a step of irradiating the stained pathological specimen with excited light to cause the emission of a fluorescent and detecting the biological substance in the pathological specimen. In the step of immunologically staining the pathological specimen, a special fluorescent particle for which the excitation wavelength appears in a region that is different from the excitation wavelength region of eosin is used as the fluorescent label.

Biological substance detection method

The present invention relates to a test support method which is a means for predicting whether or not pathological complete response (pCR) will be attained when a preoperative chemotherapy with an anticancer drug is performed, the method using a sample (breast cancer tissue section) collected from a breast cancer patient to be subjected to the preoperative chemotherapy. The test support method includes: [1] the step of acquiring a fluorescence image of a breast cancer tissue section, which fluorescence image shows bright spots of fluorescent nanoparticles labeling one or more kinds of breast cancer-related proteins; [2] the step of acquiring at least one index relating to the expression level(s) of the breast cancer-related protein(s) on the basis of the bright spots of the fluorescence image; and [3] the step of acquiring information for predicting pCR by performing an analysis using the above-described at least one index.

Test support method for supporting prediction of pathological complete response (pCR) using fluorescent nanoparticles

A tissue staining method which comprises: staining a tissue with a staining reagent wherein a biosubstance recognition site is bonded to particles carrying multiple fluorescent substances accumulated therein; in the stained tissue, counting fluorescent points or measuring fluorescent brightness; and evaluating the expression level of a biosubstance, which matches the biosubstance recognition site, in the aforesaid tissue on the basis of the number of the fluorescent points or fluorescent brightness that was measured.

Tissue staining method with staining agent containing particle holding plural phosphors

Fluorescent marker for tissue staining containing phosphor-containing nanoparticle and method using same

The present invention provides a biological substance detection method for specifically detecting a biological substance from a pathological specimen, by which method, when immunostaining using a fluorescent label and staining for morphological observation using a staining agent for morphological observation are simultaneously performed, the results of fluorescence observation and immunostaining can be assessed properly even if the fluorescent label and/or the staining agent is/are deteriorated by irradiation with an excitation light. The biological substance detection method according to the present invention is characterized in that the brightness retention rate of an immunostained part is in a range of 80% to 120% in relation to the brightness retention rate of a part stained for morphological observation when the fluorescent label used for the immunostaining is observed.

A biological substance detection method for detecting a biological substance specifically in a pathological specimen, comprising a step of immunologically staining the pathological specimen using a fluorescent label, a step of staining the pathological specimen with a staining reagent for morphology observation purposes (eosin) to observe the morphology of the pathological specimen, a step of irradiating the stained pathological specimen with excited light to cause the emission of a fluorescent and detecting the biological substance in the pathological specimen. In the step of immunologically staining the pathological specimen, a special fluorescent particle for which the excitation wavelength appears in a region that is different from the excitation wavelength region of eosin is used as the fluorescent label.

Biological substance detection method using florescent dye-containing particle

A medical image processor and storage medium are shown. According to one implementation, a medical image processor includes an input unit, an operation unit, a cell nucleus extracting unit, a fluorescent bright point extracting unit, a feature amount calculating unit, and an output unit. The input unit is used to input a cell shape image showing a shape of a cell and a fluorescent image showing expression of a specific protein as a fluorescent bright point. The operation unit is used to specify an analysis target region. The cell nucleus extracting unit extracts a region of a cell nucleus. The fluorescent bright point extracting unit extracts a fluorescent bright point. The feature amount calculating unit calculates a feature amount showing an expression amount of the specific protein. The output unit outputs the calculated feature amount.

Medical image processor and storage medium

The present invention provides a fluorescent label that can be used for carrying out a biological substance detection method for specifically detecting a biological substance from a pathological specimen, by which method, when immunostaining using a fluorescent label and staining for morphological observation using a staining agent for morphological observation are simultaneously performed, the results of fluorescence observation and immunostaining can be assessed properly even if the fluorescent label and/or the staining agent is/are deteriorated by irradiation with an excitation light. The fluorescent label is a fluorescent dye-containing nanoparticle in which the parent material is a cross-linked polymer and the fluorescent dye is an aromatic ring-based dye molecule. The cross-linked polymer is suitably a melamine resin or a styrene resin. The aromatic ring-based dye molecule is suitably a perylene and more suitably a perylene diimide. The dye molecule can have a polar group such as sulfonic acid group or its acid halide.

Fluorescent label for biological substance detection method

A medical image processor and a storage medium are shown. According to one implementation, the medical image processor includes the following. An input unit is used to input a cell shape image and a fluorescent image showing expression of a specific protein. A cell nucleus extracting unit extracts a cell nucleus. A fluorescent bright point extracting unit extracts a fluorescent bright point. A region estimating unit sets a predetermined region. When the set region does not overlap with another, it is estimated to include one cell. When a plurality of the set regions overlap, it is estimated to include a plurality of cells. A feature amount calculating unit calculates a feature amount. A determining unit determines whether each estimated cell region is cancer and determines an expression status in the region based on the calculated feature amount. An output unit outputs a determination result.

Disclosed is a fluorescent semiconductor microparticle assembly comprising at least three kinds of fluorescent semiconductor microparticles with an average particle size of from 1 to 10 nm, having the same chemical composition, a different average particle size and a different emission maximum wavelength in the emission spectra, wherein a standard deviation of emission intensity in each of the at least three kinds of fluorescent semiconductor microparticles is not more than 15%.

Fluorescent semiconductor microparticle assembly, fluorescent labeling agent assembly for biological substance, and bioimaging method and biological substance analysis method using the assemblies

A semiconductor nanoparticle and semiconductor nanorod that have optical characteristics (luminescence intensity and emission lifetime) superior to those of conventional core/shell nanosized semiconductors. There are provided a triple-layer semiconductor nanoparticle, and triple-layer semiconductor nanorod, having an average particle diameter of 2 to 50 nm and comprising a core layer, an interlayer and a shell layer, wherein the layers are composed of different crystals, and wherein the crystal constructing the shell layer exhibits a band gap greater than that of the crystal constructing the core layer, and wherein the crystal constructing the interlayer has a lattice constant assuming a value between those of the crystal constructing the core layer and the crystal constructing the shell layer.

Triple-layer semiconductor nanoparticle and triple-layer semiconductor nanorod

Disclosed are a phosphor in which prevention of aging deterioration of luminance and prevention of deterioration of discharging characteristics are compatible, a method of manufacturing the phosphor, and a plasma display panel manufactured by using the phosphor. A phosphor of the invention containing Mn as an activator is one with Mn serving as a major emission, wherein a ratio of an activator concentration in a superficial portion of a phosphor particle to an activator concentration inside the phosphor particle is 0.3-0.7.

Phosphor and plasma display panel

Nanosized semiconductor particles of a core/shell structure is disclosed, wherein the particles each comprise a core and a shell and exhibit an average particle size of not more than 100 nm and a coefficient of variation in core size distribution of not more than 30%.

Growing community of inventors

Tachikawa, Japan

Hisatake Okada